Characterization of severe COL6-related dystrophy due to the recurrent variant COL6A1 c.930+189C>T
Brain · 2025
DOI: 10.1093/brain/awaf116 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain, 2025. Verfasst von A Reghan Foley und 59 weiteren Autor:innen. Beteiligte Einrichtung: Neuromuscular and Neurogenetic Disorders of Childhood Section, Neurogenetics Branch, National Institute of Neurological Disorders and Stroke, NIH, Be…. Hauptthemen laut MEDLINE: Collagen Type VI, Muscular Dystrophies. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: GREGoR Consortium, NIH National Institute of Neurological Disorders and Stroke, Instituto de Salud Carlos III.
Abstract (Originalsprache)
Collagen VI-related dystrophies manifest with a spectrum of clinical phenotypes, ranging from Ullrich congenital muscular dystrophy (UCMD), presenting with prominent congenital symptoms and characterized by progressive muscle weakness, joint contractures and respiratory insufficiency, to Bethlem muscular dystrophy, with milder symptoms typically recognized later and at times resembling a limb girdle muscular dystrophy, and intermediate phenotypes falling between UCMD and Bethlem muscular dystrophy. Despite clinical and muscle pathology features highly suggestive of collagen VI-related dystrophy, some patients had remained without an identified causative variant in COL6A1, COL6A2 or COL6A3. With combined muscle RNA sequencing and whole-genome sequencing, we uncovered a recurrent, de novo deep intronic variant in intron 11 of COL6A1 (c.930+189C>T) that leads to a dominantly acting in-frame pseudoexon insertion. We subsequently identified and have characterized an international cohort of 44 patients with this COL6A1 intron 11 causative variant, one of the most common recurrent causative variants in the collagen VI genes. Patients manifest a consistently severe phenotype characterized by a paucity of early symptoms followed by an accelerated progression to a severe form of UCMD, except for one patient with somatic mosaicism for this COL6A1 intron 11 variant who manifests a milder phenotype consistent with Bethlem muscular dystrophy. Partial amelioration of the disease phenotype in this individual provides a strong rationale for the development of our pseudoexon skipping therapy to successfully suppress the pseudoexon insertion, resulting in normal COL6A1 transcripts. We have previously shown that splice-modulating antisense oligomers applied in vitro effectively decreased the abundance of the mutant pseudoexon-containing COL6A1 transcripts to levels comparable to the in vivo scenario of the somatic mosaicism shown here, indicating that this therapeutic approach carries significant translational promise for ameliorating the severe form of UCMD caused by this common recurrent COL6A1 variant.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neuromuscular and Neurogenetic Disorders of Childhood Section, Neurogenetics Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD 20892, USA.
- Pediatric Neurology Institute, Dana-Dwek Children's Hospital, Tel Aviv 64239, Israel.
- Clinical Trials Unit, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD 20892, USA.
- Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
- Dubowitz Neuromuscular Centre, UCL Great Ormond Street Institute of Child Health and Great Ormond Street Hospital for Children, London WC1N 1EH, UK.
- Departments of Neurology and Pediatrics, University of Utah, Salt Lake City, UT 84132, USA.
ORCID-Profile: A Reghan Foley, Janbernd Kirschner, Sidney M Gospe, Ichizo Nishino
Förderung
- GREGoR Consortium
- NIH National Institute of Neurological Disorders and Stroke
- Instituto de Salud Carlos III
- Deutsche Forschungsgemeinschaft
- NINDS NIH HHS
- NIH Medical Research Scholars Program
- the National Human Genome Research Institute
Zitieren
APA
Foley, A. R., Bolduc, V., Guirguis, F., Donkervoort, S., Hu, Y., Orbach, R., McCarty, R. M., Sarathy, A., Norato, G., Cummings, B. B., Lek, M., Sarkozy, A., Butterfield, R. J., Kirschner, J., Nascimento, A., Natera-de Benito, D., Quijano-Roy, S., Stojkovic, T., Merlini, L., …, & Lamandé, S. R. (2025). Characterization of severe COL6-related dystrophy due to the recurrent variant COL6A1 c.930+189C>T. Brain. https://doi.org/10.1093/brain/awaf116
Vancouver
Foley AR, Bolduc V, Guirguis F, Donkervoort S, Hu Y, Orbach R, et al. Characterization of severe COL6-related dystrophy due to the recurrent variant COL6A1 c.930+189C>T. Brain. 2025. doi:10.1093/brain/awaf116
BibTeX
@article{Foley2025,
author = {Foley, A Reghan and Bolduc, Véronique and Guirguis, Fady and Donkervoort, Sandra and Hu, Ying and Orbach, Rotem and McCarty, Riley M and Sarathy, Apurva and Norato, Gina and Cummings, Beryl B and Lek, Monkol and Sarkozy, Anna and Butterfield, Russell J and Kirschner, Janbernd and Nascimento, Andrés and Natera-de Benito, Daniel and Quijano-Roy, Susana and Stojkovic, Tanya and Merlini, Luciano and Comi, Giacomo and Ryan, Monique and McDonald, Denise and Munot, Pinki and Yoon, Grace and Leung, Edward and Finanger, Erika and Leach, Meganne E and Collins, James and Tian, Cuixia and Mohassel, Payam and Neuhaus, Sarah B and Saade, Dimah and Cocanougher, Benjamin T and Chu, Mary-Lynn and Scavina, Mena and Grosmann, Carla and Richardson, Randal and Kossak, Brian D and Gospe, Sidney M and Bhise, Vikram and Taurina, Gita and Lace, Baiba and Troncoso, Monica and Shohat, Mordechai and Shalata, Adel and Chan, Sophelia H S and Jokela, Manu and Palmio, Johanna and Haliloğlu, Göknur and Jou, Cristina and Gartioux, Corine and Solomon-Degefa, Herimela and Freiburg, Carolin D and Schiavinato, Alvise and Zhou, Haiyan and Aguti, Sara and Nevo, Yoram and Nishino, Ichizo and Jimenez-Mallebrera, Cecilia and Lamandé, Shireen R},
title = {Characterization of severe COL6-related dystrophy due to the recurrent variant COL6A1 c.930+189C>T},
journal = {Brain},
year = {2025},
doi = {10.1093/brain/awaf116}
}
EUVIMED